Therapeutic flag Cosmetic cross-reference

Bifonazole

CAS 60628-96-8

Bifonazole (CAS 60628-96-8) is a Phase 3 pharmaceutical compound with 4 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
14
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Bifonazole
CAS Number
60628-96-8
UNII
QYJ305Z91O
InChIKey
OCAPBUJLXMYKEJ-UHFFFAOYSA-N
ChEMBL ID
CHEMBL277535
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural producttherapeutic flag
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3
Late-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL277535 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 14 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 14869.33768115942 nM 69 -
- MIC 48.54730158730159 10'-2 umol/ml 63 -
- Potency 20304.14027777778 nM 52 -
- MIC 204931.31707317074 nM 41 -
- IC50 16157.287826086957 nM 22 -
- MIC 71.49842105263158 ug.mL-1 19 -
- MIC 50 10'-2mmol/ml 8 -
- MIC 54.28333333333333 10'-2umol 6 -
- EC50 18900 nM 2 -
- Ki 56.5 nM 1 -
Cytochrome P450 3A4
Enzyme
IC50 6.1 - Homo sapiens
Steroid 17-alpha-hydroxylase/17,20 lyase
Enzyme
Ki 7.25 - Homo sapiens
Lanosterol 14-alpha demethylase
Enzyme
IC50 6.47 - Homo sapiens
Indoleamine 2,3-dioxygenase 1
Enzyme
IC50 4.64 - Homo sapiens
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Bifonazole used for in pharmaceutical contexts?

Bifonazole (CAS 60628-96-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Bifonazole?

No adverse-event association or SIDER side-effect rows are rendered for Bifonazole in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Bifonazole also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Bifonazole with EU status "permitted".

What clinical phase is Bifonazole in?

Bifonazole is rendered with ChEMBL max phase 3.

What bioactivity targets are documented for Bifonazole?

Bifonazole has 14 bioactivity rows in this page query. Rendered target entries include Cytochrome P450 3A4, Steroid 17-alpha-hydroxylase/17,20 lyase, Lanosterol 14-alpha demethylase, Indoleamine 2,3-dioxygenase 1.